OCI-AML2 Cells

OCI-AML2 is a human acute myeloid leukemia (AML) cell line derived from the peripheral blood of a patient with acute myeloblastic leukemia without maturation (FAB classification M1). This cell line is extensively used as a model for studying the biology of AML, a hematological malignancy characterized by the clonal expansion of undifferentiated myeloid precursors in the bone marrow and peripheral blood. OCI-AML2 cells provide a valuable tool for research into leukemia pathogenesis, drug screening, and the identification of molecular targets for therapeutic intervention.

OCI-AML2 cells grow in suspension and display features consistent with immature myeloid cells. These cells harbor genetic and molecular abnormalities commonly associated with AML, including mutations in oncogenes and tumor suppressor genes, as well as dysregulated signaling pathways involved in cell survival, proliferation, and differentiation. Researchers utilize this cell line to investigate the mechanisms driving leukemogenesis, including the role of transcriptional regulators and epigenetic modifiers in maintaining the undifferentiated state of leukemic blasts.

This cell line is particularly valuable in preclinical studies for evaluating the efficacy of chemotherapeutic agents, targeted therapies, and combination treatments. It is frequently used to test inhibitors of key pathways such as FLT3, MEK/ERK, and PI3K/AKT/mTOR, which are critical to AML cell survival and proliferation. Additionally, OCI-AML2 has been used in studies on drug resistance and the development of personalized medicine approaches for AML treatment. Overall, OCI-AML2 is a robust and reliable model system for advancing research into acute myeloid leukemia and for developing novel therapeutic strategies.